Introduction
============

Hepatocellular carcinoma (HCC) was the most frequent liver cancer affecting around 700,000 patients every year[@B1]. To date, their poor prognosis remained a problem due to intrahepatic spread and extrahepatic metastasis[@B2]. Furthermore, curative treatments, like surgical resection, radiofrequency ablation, liver transplantation, were only confined to early-stage cancer[@B3]. As we know, HCC always occurred in patients with underlying chronic liver disease, such as cirrhosis patients. Therefore, it is of clinical importance to identify non-invasive risk variables for monitoring and screening high-risk patients with cirrhosis.

To date, we still remain unclear about the molecular pathogenesis of heparocarcinogenesis. However, it has been revealed that epigenetic aberrance, especially global DNA hypomethylation concomitant with locus-specific DNA hypermethylation in gene promoters, plays vital roles in carcinoma progression[@B4]-[@B7]. Additionally, alterations in DNA methylation patterns contributes to early-stage hepatocarcinogenesis[@B8] and as compared to cirrhosis, aberrantly-methylated genes tested in HCC were enriched[@B9]. Moreover, DNA methylation markers could be utilized to detect human cancers in blood, plasma, secretion, or exfoliated cytology specimens and predict the risk of cancer development[@B10]. Thus, cell free DNA (cfDNA) circulating in plasma of cirrhosis patients may represent a promising non-invasive alternative for HCC screening and monitoring.

RAS association domain family 1A (*RASSF1A*), *p16,* Secreted frizzled-related protein 1 (*SFRP1*), Embryonic liver fodrin (*ELF*), Suppressor of cytokine signaling 3 (*SOCS3*), *p53*, Glutathione S-transferaseP1 (*GSTP1*), Hepatocellular carcinoma suppressor 1 (*HCCS1*), Doublecortin domain-containing 2 (*DCDC2*), Histidine triad nucleotide-binding protein 1 (*Hint1*) hypermethylation and Long interspersed nuclear elements (*LINE1*) hypomethylation have been demonstrated to be associated with hepatocarcinogenesis[@B11]-[@B19]. Multiplex methylated sepcific PCR (multiplex MSP) was implemented to detect methylation status of candidate genes elected from database. Afterwards, we took the initiative to follow up a cohort of patients with cirrhosis to elucidate contributing risk variables, predicting HCC development, to guide monitoring and surveillance for these high-risk individuals.

Materials and Methods
=====================

Clinical specimens
------------------

Plasma and tissues samples were obtained from the West China Hospital in Sichuan University with informed consent, comprising of 119 HCC, 105 liver cirrhosis, 52 benign lesion patients (liver angioma, etal) and 50 healthy people. We collected 326 plasma specimens from above these people and 70 tissue specimens, with 40 HCC and 30 paired non-HCC tissue included, from 119 HCC patients. Among the 105 LC patients, 77 were male and 28 were female, aged from 18 to 70 years with average age being 45 years and there were 78 HBV-positive cases and 6 serum AFP \> 400ng/ml cases.

DNA extraction and Bisulfite modification
-----------------------------------------

According to the manufacturer\'s protocol, genomic DNA was extracted from plasma samples with a commercial DNA-extraction kit (AxyPrep Body Fluid Viral DNA/RNA Miniprep Kit; AxyPrep, China). Likewise, DNA was isolated from tissue samples by TIANamp Genomic DNA Kit (TIANGEN, China). 200-500ng plasma or tissue DNA was subjected to sodium bisulfite modification conducted by the EZ DNA Methylation kit (Zymo Research).

Multiplex methylated sepcific PCR
---------------------------------

To investigate the methylation status of CpG islands of *RASSF1A*, *p16*, *SFRP1*, *SOCS3* and *LINE1,* multiplex MSP was performed in a 25µL-volume reaction system, consisted of 50ng sodium-bisulfite treated DNA, isometric mixture of gene primers 3µL, 2×Master Mix 12.5µL (Qiagen, Germany) and ddH~2~O. The multiplex MSP primer sequences for *RASSF1A*, *p16*, *SFRP1*, *SOCS3* and*LINE1* were described in Table [S1](#SM0){ref-type="supplementary-material"}[@B11],[@B14],[@B20]-[@B22]. The reaction conditions were listed as follows: denaturation at 95℃ for 15 min, 30 cycles of 94℃ for 30s, annealing for 90s and 72℃ for 90s, with an ultimate extension of 10 min at 72℃. The multiplex MSP products were analyzed by capillary electrophoresis (CE).

Follow-up
---------

The LC patients were followed up through telephone calls and the average follow-up period was 30 months. They were inspected routinely with serum AFP level and abdominal ultrasonography in hospital. Also, computed Tomography (CT) was implemented together with chest radiographic examination to get aware of the disease progression.

Statistical data analysis
-------------------------

SPSS19.0 statistical software was applied for data analysis, including the Pearson\'s χ2 test or Fisher\'s exact test. Univariate and multivariate cox regression analysis were explored to estimate risk variables for patients. The overall predictive accuracy for HCC incidence was summarized by Receiver operating characteristic (ROC) curve. All P values were two-tailed and were considered significant when less than 0.05.

Results
=======

Candidate genes screened from GEPIA database and pre-experiments
----------------------------------------------------------------

The workflow chart about candidate genes selection (*RASSF1A*, *p16, SFRP1*, *ELF*, *SOCS3*, *GSTP1*, *HCCS1*, *DCDC2*, *Hint1* and*LINE1*) was shown in Fig. [1](#F1){ref-type="fig"}. Analyzed by The Gene Expression Profiling Interactive Analysis (GEPIA) database, *RASSF1A*, *p16, SFRP1*, *SOCS3* was revealed as hypermethylated genes. Subsequently, we detected the methylation status of *RASSF1A*, *p16, SFRP1*, *SOCS3*, and *LINE1* in 30 HCC and paired non-HCC tissue DNA. As shown in Fig. [2](#F2){ref-type="fig"}, abnormal methylation rate of *RASSF1A*, *p16, SFRP1*, *SOCS3*, and *LINE1* were found in 27 of 30 (90%), 26 of 30 (86.67%), 25 of 30 (83.33%), 14 of 30 (46.67%), 26 of 30 HCCs (86.67%), and 17 of 30 (56.67%), 14 of 30 (46.67%), 16 of 30 (53.33%), 10 of 30 (33.33%), 13 of 30 paired non-HCCs (43.33%) (*p*\<0.01; *p*\<0.01; *p*\<0.05; *p*\>0.05; *p*\<0.01), respectively. Thus, *SOCS3* was removed for its insignificant difference between the two cohorts. Then, we compared the concordance of methylation status of *RASSF1A*, *p16*, *SFRP1*, and *LINE1* in 40 HCC tissue DNA and paired plasma cfDNA. Accoding to the simple kappa coefficient test, *RASSF1A* was ruled out for its consistency lower than 0.4 (Table [1](#T1){ref-type="table"}). All in all, *p16, SFRP1*, and *LINE1* were enrolled in the prediction analysis.

Methylation frequency of *p16*, *SFRP1*, *LINE1* in plasma samples
------------------------------------------------------------------

To determine whether methylation status in plasma could be employed for monitoring the multistep carcinogenesis, Multiplex MSP was applied to assay the methylation status for *p16*, *SFRP1*, and *LINE1* in plasma specimens of 119 HCC patients, 105 LC patients, 52 patients with benign lesions and 50 healthy people (Figure [S1](#SM0){ref-type="supplementary-material"}). Aberrant methylation of *p16*, *SFRP1*, and *LINE1* was measured in 85 of 119 (71.43%), 73 of 119 (61.34%), 80 of 119 (67.23%) HCCs, in 41 of 105 (39.05%), 37 of 105 (35.24%), 23 of 105 (21.90%) cirrhotic livers, in 2 of 52 (3.85%), 1 of 52 (1.92%), 0 of 52 (0%) patients with benign lesions, seperately, and no aberrant methylation was detected in normal people (*p\<*0.01) (Figure [3](#F3){ref-type="fig"}). The average number of aberrantly-methylated gene in healthy subjects, benign lesions, LC, and HCC patients was enriched gradually from 0, 0.06, 0.96 to 2.33, certifying that hepatocarcinogenesis was associated with increasing DNA methylation.

The concurrent analysis of age and plasma *p16*, *SFRP1*, *LINE1* methylation could promote the overall accuracy for HCC incidence prediction among LC patients
---------------------------------------------------------------------------------------------------------------------------------------------------------------

After the methylation status of *p16*, *SFRP1*, and *LINE1* in plasma cfDNA was investigated, 105 cirrhosis patients were followed up in a median period of 30 months. 32 out of them developed HCC and the HCC incidence rate was 30.48%. Then, we summarized the risk factors (Age, gender, HBsAg, Anti-HCV, and AFP level) and abnormally-methylated genes (*p16*, *SFRP1*, and *LINE1*) to participate in the univariate and multivariate cox analysis (Table [2](#T2){ref-type="table"}). As data demonstrated, patients\' age and aberrant methylation of *p16*, *SFRP1*, and *LINE1* were statistically related with HCC development among the 105 high-risk individuals. Aimed to explore whether the concurrent four risk variables were superior for HCC development, we analyzed the sensitivity, specificity and predictive accuracy with the use of singe or multi-risk panels based on Receiver operating characteristic (ROC) curve. Table [3](#T3){ref-type="table"} presented that along with the increased number of risk variables enrolled in HCC incidence prediction, the overall accuracy kept an elevating trend. Most importantly, the sensitivity, specificity, and overall predictive accuracy reached the highest with the prediction panel containing the four variables together (93.8%, 63.0%, 90.7%, respectively).

HCC incidence rate elevated along with the growth of age or increased number of abnormally-methylated gene
----------------------------------------------------------------------------------------------------------

According to the diverse age, we divided high-risk populations into three groups, namely, 0-40 years group (n=20), 40-55 years group (n=57), 55-70 years group (n=28), and calculated their respective HCC incidence rate. As the histogram showed, HCC incidence rate gradually lifted from 10%, 12.28%, to 82.14% (*P\<*0.01) along with the older age. Subsequently, HCC incidence rate of the three groups was computed in non-HCC and HCC cohorts and was dramatically raised in 55-70 years group (7%-72%) (Figure [4](#F4){ref-type="fig"}A). Analogously, HCC incidence rate lifted along with the increased number of aberrantly-methylated gene. Compared with patients with 0-1 aberrantly-methylated gene (17.44%), patients with 2-3 aberrantly-methylated genes were more likely to suffer from HCC development (89.47%). Moreover, in the fan chart of HCC group, patients with 2-3 aberrantly-methylated genes took up a thumping majority (53%), in comparison with non-HCC group (3%) (Figure [4](#F4){ref-type="fig"}B).

Risk group classification based on the concurrent analysis of age and number of abnormally-methylated gene
----------------------------------------------------------------------------------------------------------

105 high-risk populations were separated into five groups (Table [4](#T4){ref-type="table"}) and computed the respective HCC incidence rate (Figure [5](#F5){ref-type="fig"}), that is, group 1 (0-40 years with 0-1 aberrantly-methylated gene, n=20; 5.00%), group 2 (40-55 years with 0-1 aberrantly-methylated gene, n=52; 7.69%), group 3 (40-55 years with 2-3 aberrantly-methylated genes, n=8; 87.50%), group 4 (55-70 years with 0-1 aberrantly-methylated gene, n=15; 73.33%), and group 5 (55-70 years with 2-3 aberrantly-methylated genes, n=10; 90.00%). The incidence rate of group 3, 4, and 5 was statistically significant than group 1 and 2 (*P\<*0.0001) (Figure [5](#F5){ref-type="fig"}A). Hence, we regarded patients with the age of 40-55 years coupled with 2-3 aberrantly-methylated genes, 55-70 years coupled with 0-1 aberrantly-methylated gene, and 55-70 years coupled with 2-3 aberrantly-methylated genes as the high-risk group (n=33), and patients with the age of 0-40 years coupled with 0-1 aberrantly-methylated gene and 40-55 years coupled with 0-1 aberrantly-methylated gene as the low-risk group (n=72). The incidence rate between the two risk groups was statistically significant (*P\<*0.0001) (Figure [5](#F5){ref-type="fig"}B). Ultimately, high-risk cirrhosis patients with 55-over years or 2-3 aberrantly-methylated genes should be paid more attention with regular monitoring and screening of HCC development.

Discussion
==========

In previous investigations, older age[@B23]-[@B24], male sex[@B25]-[@B26], severity of compensated cirrhosis at presentation, and sustained activity of liver disease[@B27] are important predictors of HCC incidence. Whereas, in this study, significant efforts had been put emphasis on the discovery and detection of other biomakers for early warning of high-risk individuals with cirrhosis for HCC incidence. It seemed that Promoter methylation appeared to be one of the earliest epigenetic abnormalities in human hepatocarcinogenesis[@B28]-[@B29]. And the molecular alteration could be already detectable in cirrhosis, representing a premalignant liver condition as overwhelming majority of HCC arised in the context of liver cirrhosis[@B30]. Above all, thus far, fewer than 20% of cirrhosis patients were efficaciously enrolled in surveillance programs[@B31]. These findings demonstrated the promise of gene promoter aberrant methylation in plasma as a molecular marker for identifying high-risk cirrhosis patients, more likely to suffer from cancer development[@B32].

Present studies have suggested that expression alterations of *p16, SFRP1*, and*LINE1* were intimately implicated in hepatocarcinogenesis. Thus, the aberrant methylation of the three genes was included as biomarkers for screening and monitoring high-risk patients with cirrhosis. We observed that the average number of aberrantly methylated gene showed an increase from the progression of cirrhosis to HCC, consistent with the previous reports[@B11]. Whereafter, among 105 LC cases, who were investigated the three genes\' methylation status, 32 patients developed HCC in a short follow-up period. Multivariate analysis suggested that HCC incidence was significantly depending on age and the aberrant methylation of *p16*, *SFRP1*, and *LINE1*, which could be considered as candidate contributing variables for HCC development. ROC analysis indicated that concurrent analysis of the four variables had a overall 90.7% predictive accuracy. Addtionally, HCC incidence rate was greatly in line with the increase of aberrantly-methylated gene\' s number, which was in accordance with the result that genes epigenetically altered in HCC were significantly enriched along with HCC development[@B30]. Identification of risk variables for HCC incidence among high-risk patients with cirrhosis was extremely momentous, because they can be screened carefully in case of HCC incidence and given potentially curative treatments. According to the data suggested, patients with ≥55 years old or 2-3 abnormally-methylated genes may have the higher risk with HCC incidence, which may be valuable in assessing the risk of HCC incidence among high-risk individuals during a short period.

Conclusions
===========

This is the first study to prospectively examine the relationship between epigenetic alterations in heparocarcinogenesis-related genes, clinical characteristics and HCC incidence among cirrhosis patients to guide monitoring and surveillance for these high-risk populations.
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![Frequency of abnormal methylation in tissue DNA of *RASSF1A*, *p16*, *SFRP1*, *SOCS3*, and *LINE1* among 30 HCC and paired non-HCC specimens. HCC, hepatocellular carcinoma; *RASSF1A*, RAS association domain family 1A; *SFRP1*, Secreted frizzled-related protein 1; *SOCS3*, Suppressor of cytokine signaling 3; *LINE1*, Long interspersed nuclear element.](jcav09p2203g001){#F2}
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![Frequency of abnormal methylation in plasma DNA of *p16*, *SFRP1* and *LINE1* among 119 HCC, 105 LC, 52 benign liver disease patients and 50 healthy subjects. *SFRP1*, Secreted frizzled-related protein 1; *LINE1*, Long interspersed nuclear element; HCC, Hepatocellular carcinoma; LC, Liver cirrhosis; BLD, Benign liver diseases; HS, Healthy subjects.](jcav09p2203g003){#F3}

![HCC incidence rate elevated along with the growth of age (A) or increased number of abnormally-methylated gene (B). The proportion of patients\' age and the number of abnormally methylated genes were distinctly different between non-HCC and HCC group among 105 cases and the HCC incidence rate dramatically lifted among LC patients with ≥55 years or more than 2 abnormally-methylated genes.](jcav09p2203g004){#F4}

![Risk group classification based on the concurrent analysis of age and number of abnormally-methylated gene. (A). The relationship between HCC incidence rate and groups divided by diverse age and number of aberrantly-methylated gene. (B). High-risk and low-risk groups were defined according to the distinct difference of HCC incidence rate.](jcav09p2203g005){#F5}

###### 

Comparison of the concordance of methylation status for six genes in 40 HCC cases and tumor plasma (Simple kappa coefficient).

  Gene        Tumor tissue (n,%)   Corresponding tumor plasma (n,%)   *P*-value   *Kappa*
  ----------- -------------------- ---------------------------------- ----------- ---------
  *RASSF1A*   36 (90.0)            29 (72.5)                          0.025       0.297
  *p16*       31 (77.5)            27 (67.5)                          0.000       0.628
  *SFRP1*     29 (72.5)            22 (55.0)                          0.000       0.634
  *LINE1*     30 (75.0)            23 (57.5)                          0.000       0.514

###### 

Univariate anaysis and multivariate analysis of 105 patients with cirrhosis liver in relation to HCC development.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable\                 No.of patients   No. of patients with HCC incidence   Univariate anaysis       multivariate analysis                         
  (n=61)                                                                                                                                                 
  ------------ ------------ ---------------- ------------------------------------ ------------------------ ----------------------- --------------------- -------
  Age          \>50 years   44               25                                                                                                          

               ≤50 years    61               7                                    6.203 (2.672-14.382)     0.000                   0.355 (0.144-0.874)   0.024

  Gender       Male         77               23                                                                                                          

               Female       28               9                                    0.937 (0.434-2.026)      0.869                   0.996 (0.437-2.270)   0.992

  AFP (μg/L)   ≥400         6                4                                                                                                           

               \<400        99               28                                   5.081 (1.770-14.583)     0.003                   1.609 (0.405-6.399)   0.500

  HBsAg        \+           78               29                                                                                                          

               \-           27               3                                    3.768 (1.148-12.375)     0.029                   0.614 (0.165-2.286)   0.467

  Anti-HCV     \+           2                0                                                                                                           

               \-           103              32                                   0.048 (0.000-1744.723)   0.570                   14020.160 (0.000-)    0.982

  *p16*        M            41               19                                                                                                          

               U            64               13                                   2.837 (1.398-5.754)      0.004                   0.327 (0.154-0.696)   0.004

  *SFRP1*      M            37               18                                                                                    \- -                  

               U            68               14                                   2.975 (1.476-5.293)      0.002                   0.111 (0.037-0.327)   0.000

  *LINE1*      M            23               16                                                                                                          

               U            82               16                                   0.186 (0.093-0.373)      0.000                   0.068 (0.022-0.209)   0.000
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of the predictive accuracy of age and plasma *p16*, *SFRP1*, *LINE1* methylation, when used alone or combined, in liver cirrhosis patients.

                          Sensitivity   Specificity   AUC (Area under curve)   Youden index
  ----------------------- ------------- ------------- ------------------------ --------------
  Age                     78.10%        28.8%         74.7%                    0.50
  *SFRP1*                 56.3%         26.0%         65.1%                    0.50
  *LINE1*                 50.0%         8.2%          70.9%                    0.50
  *p16*                   59.4%         31.5%         63.9%                    0.50
  Age+*SFRP1*             87.5%         34.2%         82.4%                    0.23
  Age+*LINE1*             96.9%         31.5%         86.5%                    0.23
  Age+*p16*               78.1%         39.7%         77.2%                    0.22
  *SFRP1+LINE1*           87.5%         34.2%         82.4%                    0.23
  *SFRP1+p16*             75.0%         54.8%         70.3%                    0.23
  *LINE1+p16*             78.1%         39.7%         77.2%                    0.22
  Age+*SFRP1+LINE1*       96.9%         31.5%         88.8%                    0.17
  Age+*SFRP1+p16*         93.8%         63.0%         86.8%                    0.08
  Age+*LINE1+p16*         96.9%         31.5%         89.6%                    0.19
  *SFRP1+LINE1+p16*       93.8%         63.0%         86.8%                    0.19
  Age+*SFRP1+p16+LINE1*   93.8%         63.0%         90.7%                    0.19

###### 

Groups classification based on concurrent analysis with diverse age and number of aberrantly-methylated gene.

  Group                                              105 cases (n)   HCC incidence (n)   HCC incidence rate (%)
  -------------------------------------------------- --------------- ------------------- ------------------------
  0-40 years with 0-1 aberrantly-methylated gene     20              1                   5.00%
  0-40 years with 2-3 aberrantly-methylated genes    0               \-                  \-
  40-55 years with 0-1 aberrantly-methylated gene    52              4                   7.69%
  40-55 years with 2-3 aberrantly-methylated genes   8               7                   87.50%
  55-70 years with 0-1 aberrantly-methylated gene    15              11                  73.33%
  55-70 years with 2-3 aberrantly-methylated genes   10              9                   90.00%
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